5th Feb 2019 09:18
LONDON (Alliance News) - Evgen Pharma PLC on Tuesday said it has completed patient recruitment in its SAS phase II trial for proposed treatment SFX-01.
SFX-01 is a planned treatment for a subarachnoid haemorrhage, an uncommon type of stroke.
The company said, in line with market expectations, it forecasts the read-out of the primary endpoints of the trial in the second quarter of 2019.
The SAS trial is a randomised, double blind, placebo-controlled trial which has now recruited 90 patients. The primary endpoints of SAS relate to safety, tolerability, and blood flow.
The "important secondary endpoints", which include the assessment of patients' cognitive function at three and six months post haemorrhage, will read-out in late summer 2019, the company added.
Furthermore, Evgen said the last patient recruited in the STEM trial of SFX-01 in metastatic breast cancer has now completed her last visit, having reached the 24-week end-point without disease progression.
Evgen shares were trading up 2.5% at 16.15 pence each early Tuesday.
Related Shares:
EVG.L